Synendos Therapeutics was selected for BaseLaunch Phase I and received CHF 10'000.
https://www.baselaunch.ch/portfolio/
September 2019 // Funding
Updated: Nov 6, 2020
FOUNDING TEAM
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.
FOUNDING TEAM
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.
FOUNDING TEAM
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.
FOUNDING TEAM
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.
PD Dr. Andrea Chicca
Project leader/senior scientist at UniBern.
2 years in pharma industry.
8 years of research activity on the ECS
Prof. Dr. Jürg Gertsch
Full Professor at UniBern.
Collaboration with pharma industry.
10+ years of research activity on the ECS.
Recent Posts
See AllSynendos Series A Extension Synendos Therapeutics is thrilled to announce an extension to the Series A financing with the addition of Ysios Capital to its syndicate of European investors. Ysios Capita
Synendos Therapeutics Raises CHF 20 Million in Series A Financing.
Synendos and Prof. Jürg Gertsch received an Innosuisse Innovation Grant (total value of CHF 950’000).